-
Je něco špatně v tomto záznamu ?
Distinctive autophagy/mitophagy biomarker profiles in frontotemporal lobar degeneration and Alzheimer's disease
K. Veverová, A. Katonová, H. Horáková, J. Laczó, F. Angelucci, J. Hort, S. Lautrup, EF. Fang, M. Vyhnálek
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články
Grantová podpora
TO01000215
KAPPA programme
LX22NPO5107
National Institute for Neurological Research
6980382
Institutional Support of Excellence
NLK
BioMedCentral
od 2013-01-12
BioMedCentral Open Access
od 2013
Directory of Open Access Journals
od 2013
Free Medical Journals
od 2013
PubMed Central
od 2013
Europe PubMed Central
od 2013
ProQuest Central
od 2015-01-01
Open Access Digital Library
od 2013-01-01
Open Access Digital Library
od 2013-01-01
Health & Medicine (ProQuest)
od 2015-01-01
ROAD: Directory of Open Access Scholarly Resources
od 2013
Springer Nature OA/Free Journals
od 2013-12-01
- MeSH
- Alzheimerova nemoc * krev patologie mozkomíšní mok MeSH
- autofagie * fyziologie MeSH
- biologické markery * mozkomíšní mok krev MeSH
- frontotemporální lobární degenerace * patologie mozkomíšní mok krev MeSH
- homolog Atg1 metabolismus MeSH
- intracelulární signální peptidy a proteiny MeSH
- lidé středního věku MeSH
- lidé MeSH
- mitofagie * MeSH
- proteinkinasy metabolismus krev MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
Maintaining cellular homeostasis by removing damaged and senescent mitochondria, a process termed mitophagy, is crucial in preventing Alzheimer's disease (AD) and represents a promising therapeutic target. Our previous research revealed altered mitophagy biomarkers, such as increased CSF and serum PINK1 and serum BNIP3L and decreased serum TFEB levels, indicating impaired autophagy-lysosomal degradation in the AD continuum. However, the role of autophagy/mitophagy in frontotemporal lobar degeneration (FTLD) remains unclear. This study investigated the biomarkers of autophagy/mitophagy and lysosomal biogenesis (PINK1, ULK1, BNIP3L, and TFEB) in biofluids (CSF and serum) from 308 biomarker-defined individuals across the FTLD continuum (FTLD-dementia, n = 29; FTLD-MCI, n = 33) and compared them with those across the AD continuum (MCI-AD, n = 100; AD-dementia, n = 100) and cognitively unimpaired (CU) controls (n = 46) recruited from Czech Brain Aging Study. Additionally, we compared the mitophagy biomarkers across different FTLD clinical subtypes (frontal, semantic and nonfluent variant) with CU, and explored the association between mitophagy biomarkers and clinical phenotypes of FTLD (biomarkers of tau, biomarkers of neurodegeneration, cognition and ATN profile).Our findings indicated a significantly lower CSF PINK1 and ULK1 levels in FTLD compared to AD, with FTLD dementia showing particularly low CSF PINK1 levels compared to AD-dementia. Conversely, CSF ULK1 levels were higher in FTLD-MCI compared to AD-dementia. Serum analyses revealed lower PINK1 and higher TFEB levels in FTLD dementia compared to AD dementia. This study provides compelling evidence of distinct alterations in autophagy/mitophagy biomarkers between FTLD and AD, indicating that these neurodegenerative diseases may affect the cellular waste disposal system through different pathways. This is the first study to explore mitophagy biomarkers in human CSF and serum in FTLD, opening avenues for further research and potential clinical applications.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25009842
- 003
- CZ-PrNML
- 005
- 20250429135538.0
- 007
- ta
- 008
- 250415s2025 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1186/s40478-025-01954-9 $2 doi
- 035 __
- $a (PubMed)39972393
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Veverová, Kateřina $u Memory Clinic, Department of Neurology, 2nd Faculty of Medicine, Charles University and Motol University Hospital, V Úvalu 84, Prague 5, 150 06, Czech Republic $1 https://orcid.org/0000000258451854
- 245 10
- $a Distinctive autophagy/mitophagy biomarker profiles in frontotemporal lobar degeneration and Alzheimer's disease / $c K. Veverová, A. Katonová, H. Horáková, J. Laczó, F. Angelucci, J. Hort, S. Lautrup, EF. Fang, M. Vyhnálek
- 520 9_
- $a Maintaining cellular homeostasis by removing damaged and senescent mitochondria, a process termed mitophagy, is crucial in preventing Alzheimer's disease (AD) and represents a promising therapeutic target. Our previous research revealed altered mitophagy biomarkers, such as increased CSF and serum PINK1 and serum BNIP3L and decreased serum TFEB levels, indicating impaired autophagy-lysosomal degradation in the AD continuum. However, the role of autophagy/mitophagy in frontotemporal lobar degeneration (FTLD) remains unclear. This study investigated the biomarkers of autophagy/mitophagy and lysosomal biogenesis (PINK1, ULK1, BNIP3L, and TFEB) in biofluids (CSF and serum) from 308 biomarker-defined individuals across the FTLD continuum (FTLD-dementia, n = 29; FTLD-MCI, n = 33) and compared them with those across the AD continuum (MCI-AD, n = 100; AD-dementia, n = 100) and cognitively unimpaired (CU) controls (n = 46) recruited from Czech Brain Aging Study. Additionally, we compared the mitophagy biomarkers across different FTLD clinical subtypes (frontal, semantic and nonfluent variant) with CU, and explored the association between mitophagy biomarkers and clinical phenotypes of FTLD (biomarkers of tau, biomarkers of neurodegeneration, cognition and ATN profile).Our findings indicated a significantly lower CSF PINK1 and ULK1 levels in FTLD compared to AD, with FTLD dementia showing particularly low CSF PINK1 levels compared to AD-dementia. Conversely, CSF ULK1 levels were higher in FTLD-MCI compared to AD-dementia. Serum analyses revealed lower PINK1 and higher TFEB levels in FTLD dementia compared to AD dementia. This study provides compelling evidence of distinct alterations in autophagy/mitophagy biomarkers between FTLD and AD, indicating that these neurodegenerative diseases may affect the cellular waste disposal system through different pathways. This is the first study to explore mitophagy biomarkers in human CSF and serum in FTLD, opening avenues for further research and potential clinical applications.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a Alzheimerova nemoc $x krev $x patologie $x mozkomíšní mok $7 D000544
- 650 12
- $a frontotemporální lobární degenerace $x patologie $x mozkomíšní mok $x krev $7 D057174
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a senioři $7 D000368
- 650 12
- $a biologické markery $x mozkomíšní mok $x krev $7 D015415
- 650 12
- $a mitofagie $7 D063306
- 650 12
- $a autofagie $x fyziologie $7 D001343
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a senioři nad 80 let $7 D000369
- 650 _2
- $a proteinkinasy $x metabolismus $x krev $7 D011494
- 650 _2
- $a homolog Atg1 $x metabolismus $7 D000071189
- 650 _2
- $a intracelulární signální peptidy a proteiny $7 D047908
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Katonová, Alžběta $u Memory Clinic, Department of Neurology, 2nd Faculty of Medicine, Charles University and Motol University Hospital, V Úvalu 84, Prague 5, 150 06, Czech Republic
- 700 1_
- $a Horáková, Hana $u Memory Clinic, Department of Neurology, 2nd Faculty of Medicine, Charles University and Motol University Hospital, V Úvalu 84, Prague 5, 150 06, Czech Republic
- 700 1_
- $a Laczó, Jan $u Memory Clinic, Department of Neurology, 2nd Faculty of Medicine, Charles University and Motol University Hospital, V Úvalu 84, Prague 5, 150 06, Czech Republic
- 700 1_
- $a Angelucci, Francesco $u Memory Clinic, Department of Neurology, 2nd Faculty of Medicine, Charles University and Motol University Hospital, V Úvalu 84, Prague 5, 150 06, Czech Republic
- 700 1_
- $a Hort, Jakub $u Memory Clinic, Department of Neurology, 2nd Faculty of Medicine, Charles University and Motol University Hospital, V Úvalu 84, Prague 5, 150 06, Czech Republic
- 700 1_
- $a Lautrup, Sofie $u Department of Clinical Molecular Biology, University of Oslo and Akershus University Hospital, Lørenskog, 1478, Norway $u The Norwegian Centre on Healthy Ageing (NO-Age), Oslo, Norway
- 700 1_
- $a Fang, Evandro Fei $u Department of Clinical Molecular Biology, University of Oslo and Akershus University Hospital, Lørenskog, 1478, Norway. e.f.fang@medisin.uio.no $u The Norwegian Centre on Healthy Ageing (NO-Age), Oslo, Norway. e.f.fang@medisin.uio.no
- 700 1_
- $a Vyhnálek, Martin $u Memory Clinic, Department of Neurology, 2nd Faculty of Medicine, Charles University and Motol University Hospital, V Úvalu 84, Prague 5, 150 06, Czech Republic. martin.vyhnalek@lfmotol.cuni.cz $1 https://orcid.org/0000000259764932 $7 xx0070891
- 773 0_
- $w MED00209779 $t Acta neuropathologica communications $x 2051-5960 $g Roč. 13, č. 1 (2025), s. 37
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/39972393 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250415 $b ABA008
- 991 __
- $a 20250429135533 $b ABA008
- 999 __
- $a ok $b bmc $g 2311307 $s 1246923
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2025 $b 13 $c 1 $d 37 $e 20250220 $i 2051-5960 $m Acta neuropathologica communications $n Acta Neuropathol Commun $x MED00209779
- GRA __
- $a TO01000215 $p KAPPA programme
- GRA __
- $a LX22NPO5107 $p National Institute for Neurological Research
- GRA __
- $a 6980382 $p Institutional Support of Excellence
- LZP __
- $a Pubmed-20250415